[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655180":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":26,"overallOfficials":13,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":13,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":13,"enrollmentInfo":66,"targetDuration":13,"studyType":69,"phases":70,"briefSummary":71,"conditions":72,"keywords":80,"overallStatus":89,"whyStopped":13,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Vanderbilt University Medical Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"13C6-Glucose Uptake and Metabolism in Immune Cells","Following 13C6-glucose infusion, peripheral blood immune cell populations will be magnetically isolated from collected blood and analyzed by mass spectrometry to quantify 13C6-glucose and downstream 13C-labeled metabolites.","Up to 4 hours",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","BASIC_SCIENCE",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21],{"label":22,"type":6,"description":23,"interventionNames":24},"13C6-Glucose","Participants will receive 10-25 grams of 13C6-glucose intravenously over 2-4 hours during a single ICU study procedure.",[25],"Drug: 13C6-Glucose",[27],{"type":28,"name":22,"description":29,"armGroupLabels":30,"otherNames":13},"DRUG","Compounded as 5% 13C6-glucose in water and given intravenously over 2-4 hours at a total dose of 10-25 grams.",[22],[32],{"name":33,"role":34,"phone":35,"phoneExt":13,"email":36},"Matthew T Stier, M.D., Ph.D.","CONTACT","615-875-4978","matthew.stier@vumc.org",[38],{"facility":5,"status":13,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Nashville","Tennessee","37212","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-86.78444,36.16589,{"lat":48,"lon":47},[51,52],{"name":33,"role":34,"phone":35,"phoneExt":13,"email":36},{"name":33,"role":53,"phone":13,"phoneExt":13,"email":13},"PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"Matthew Stier","Assistant Professor of Medicine","100655180","tracing-of-real-time-glu13cose-metabolism-in-human-immune-cells---intensive-care-unit-100655180",false,"NCT07811180","Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells - Intensive Care Unit","TORCH-ICU","Inclusion Criteria:\n\n* Adults aged 18 or older\n* Admitted to one of the following VUMC adult ICUs: Medical ICU, Pulmonary ICU\n* The participant or legally authorized representative must agree to the genetic analyses required as part of this study\n\nExclusion Criteria:\n\n* Pregnant\n* Prisoner or in police custody\n* Patient desires comfort measures only or has a goals-of-care plan inconsistent with participation in non-beneficial research procedures\n* Hemoglobin less than 8 g\u002FdL\n* Uncontrolled hyperglycemia (persistent blood glucose \\>300 mg\u002FdL) or any clinical condition in which additional IV glucose administration is not appropriate in the opinion of the Study Coordinator, PI, or treating ICU team\n* Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500 mL in an 8-week period\n* Unable to safely obtain vascular access required for study infusion and blood collection\n* Clinical instability or anticipated clinical care needs that would make the study procedure inappropriate at that time in the opinion of the Study Coordinator, PI, or treating ICU team\n* Any medical issue or pharmacologic exposure which, in the opinion of the study investigator, might interfere with the study objectives\n* Any reason which, in the opinion of the study investigator, adds additional risk to the patient","ALL","18 Years",{"count":67,"type":68},25,"ESTIMATED","INTERVENTIONAL",[15],"The purpose of this study is to understand how cells of the immune system use the common sugar glucose during critical illness. Investigators will intravenously infuse a non-radioactive carbon-13 glucose tracer into adult intensive care unit (ICU) participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.",[73,74,75,76,77,78,79],"Glucose","Metabolism","Isotope Labeling","Immune System and Related Disorders","Critical Illness","Intensive Care Unit (ICU)","Sepsis",[81,82,83,84,77,85,74,73,79,86,87,88],"Immunometabolism","Stable Isotope Tracing","Immune Cell Metabolism","Intensive Care Unit","Critical Care","Septic Shock","Acute Respiratory Distress Syndrome","ARDS","NOT_YET_RECRUITING","2026-09-02",{"date":92,"type":93},"2026-09-09","ACTUAL",{"date":95,"type":68},"2026-11-01",{"date":97,"type":68},"2028-03-01",{"name":5,"class":6},1]